Cargando…

Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice

BACKGROUND: The safety of pirfenidone on pulmonary fibrosis patients with other kinds of interstitial lung diseases (ILDs) in addition to idiopathic pulmonary fibrosis (IPF) is unknown. Furthermore, its effectiveness-related factors on IPF patients are not quite explored. METHODS: A retrospective st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Chuling, Huang, Hui, Guo, Jian, Ferianc, Martin, Xu, Zuojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992179/ https://www.ncbi.nlm.nih.gov/pubmed/31999801 http://dx.doi.org/10.1371/journal.pone.0228390

Ejemplares similares

Relation between sex hormones and leucocyte telomere length in men with idiopathic pulmonary fibrosis
por: Fang, Chuling, et al.
Publicado: (2020)

Whole-exome sequencing identifies susceptibility genes and pathways for idiopathic pulmonary fibrosis in the Chinese population
por: Fang, Chuling, et al.
Publicado: (2021)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Immunological Evidence for the Role of Mycobacteria in Sarcoidosis: A Meta-Analysis
por: Fang, Chuling, et al.
Publicado: (2016)

A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis
por: Dhooria, Sahajal, et al.
Publicado: (2020)

Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital
por: Song, Myung Jin, et al.
Publicado: (2020)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2017)

Adverse Events of Pirfenidone for the Treatment of Pulmonary Fibrosis: A Meta-Analysis of Randomized Controlled Trials
por: Jiang, Chunguo, et al.
Publicado: (2012)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2018)

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Wencel, Mark L., et al.
Publicado: (2018)

Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study
por: Eaden, James A., et al.
Publicado: (2020)

Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study
por: Hwang, Hyeontaek, et al.
Publicado: (2022)

Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
por: Gulati, Swati, et al.
Publicado: (2020)

Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra
por: Kuronuma, Koji, et al.
Publicado: (2022)

Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice
por: Fonseca, Joaquim
Publicado: (2015)

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
por: Vietri, Lucia, et al.
Publicado: (2020)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
por: Miedema, Jelle R., et al.
Publicado: (2022)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017)

Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis
por: Shi, Hanyu, et al.
Publicado: (2020)

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis
por: Wijsenbeek, Marlies S., et al.
Publicado: (2015)

Exome Sequencing Reveals Genetic Variability and Identifies Chronic Prognostic Loci in Chinese Sarcoidosis Patients
por: Zhang, Qian, et al.
Publicado: (2022)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data
por: Kim, Jiwon, et al.
Publicado: (2023)

Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: A systematic review and meta-analysis
por: Hou, Liyan, et al.
Publicado: (2023)

Pirfenidone: an update on clinical trial data and insights from everyday practice
por: Kreuter, Michael
Publicado: (2014)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
por: Sakayori, Masashi, et al.
Publicado: (2019)

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
por: Colbert, Gates, et al.
Publicado: (2022)

Protective efficacy of pirfenidone in rats with pulmonary fibrosis induced by bleomycin
por: Demirkol, Barış, et al.
Publicado: (2023)

“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64.
Publicado: (2015)

Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients
por: Huang, Hui, et al.
Publicado: (2015)

Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
por: Alhamad, Esam H.
Publicado: (2015)

Pirfenidone improves survival in IPF: results from a real-life study
por: Margaritopoulos, George A., et al.
Publicado: (2018)

Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease
por: Mandovra, Neha P., et al.
Publicado: (2023)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_07be6asajgcsf09lt814hjkf2f